Bcel stock forecast.

April 06, 2023 — 09:55 am EDT. Written by Zacks Equity Research for Zacks ->. Shares of Atreca, Inc. (BCEL) have been struggling lately and have lost 20% over the past week. However, a hammer ...The current Atreca [ BCEL] share price is $0.21. The Score for BCEL is 45, which is 10% below its historic median score of 50, and infers higher risk than normal. BCEL is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.Stock Analyst Price Targets - Review. Analysts average stock forecasts to be materialized ratio is 4.17% with an average time for these price targets to be met of 0.17 days. Highest price target for BCEL is 5, Lowest price target is 1, average price target is 3. Most recent stock forecast was given by ROBERT DRISCOLL from WEDBUSH on 14 …Atreca Inc Cl A (BCEL) Company Description. Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism ... Analyst Forecast. According to 5 analysts, the average rating for BCEL stock is "Hold." The 12-month stock price forecast is $3.38, which is an increase of 1,479.44% from the latest price.

Stock Price Forecast. The 4 analysts offering 12-month price forecasts for Atreca Inc have a median target of 1.50, with a high estimate of 9.00 and a low estimate of 1.00. The median estimate represents a +500.00% increase from the last price of 0.25.See ENTHUSIAST GAMING HOLDINGS INC stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ... Forecast . Price target. 1.93 0.00 0.00%. The 7 analysts offering 1 year price forecasts for EGLX have a max estimate of — and a min estimate of —.

Track Atreca Inc - Ordinary Shares - Class A (BCEL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors The current Cheniere Energy [ LNG] share price is $179.21. The Score for LNG is 45, which is 10% below its historic median score of 50, and infers higher risk than normal. LNG is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.

Atreca Inc (NASDAQ:BCEL) 0.2302. Delayed Data. As of Nov 30. +0.0047 / +2.19%. Today’s Change. 0.19. Today ||| 52-Week Range. 2.05.Zacks News for BCEL Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37% 08/14/23-9:51AM EST Zacks Here's Why Atreca, Inc. (BCEL) Is a Great 'Buy the Bottom' Stock Now 04/06/23-8:55AM EST ...Weather forecasts are essential tools for planning our daily activities, especially when it comes to the next 10 days. Understanding a weather 10 day forecast can help us make informed decisions about outdoor events, travel plans, or even w...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Cheniere Energy share forecasts, stock quote and buy / sell signals below. According to present data Cheniere Energy's LNG shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).

CRNT Earnings Forecast. Next quarter’s earnings estimate for CRNT is $0.06 with a range of $0.06 to $0.06. The previous quarter’s EPS was $0.06. CRNT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 66.36% of the time in the same period. In the last calendar year CRNT has ...

Stock Price Forecast. The 4 analysts offering 12-month price forecasts for Allakos Inc have a median target of 9.50, with a high estimate of 22.00 and a low estimate of 1.50. The median estimate ...

Nov 28, 2023 · A high-level overview of Atreca, Inc. (BCEL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Stock Price Forecast. The 18 analysts offering 12-month price forecasts for Nu Holdings Ltd have a median target of 9.75, with a high estimate of 16.00 and a low estimate of 6.00. The median ...Nov 16, 2023 · Analysts have been projecting $1.00 as a low price target for the stock while placing it at a high target of $9.00. It follows that stock’s current price would drop -4400.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -400.0% for stock’s current value. Atreca Inc (BCEL) estimates and forecasts Stock Price Forecast. The 4 analysts offering 12-month price forecasts for Allakos Inc have a median target of 9.50, with a high estimate of 22.00 and a low estimate of 1.50. The median estimate ... Fiscal Q3 2023 ended 9/30/23. Get the latest Atreca Inc (BCEL) real-time quote, historical performance, charts, and other financial information to help you make more informed …How much is Atreca stock worth today? ( NASDAQ: BCEL) Atreca currently has 39,295,661 outstanding shares. With Atreca stock trading at $0.27 per share, the total value of Atreca stock (market capitalization) is $10.41M. Atreca stock was originally listed at a price of $18.05 in Jun 20, 2019.

The rating of the stock has changed to hold according to some analysts. It's at an all time low, buy folks thanks me later. Recently BCEL has reached an all time low and a data suggests that is will rise back up. According to Fintel.IO Blackrock has bought a staggering 350k shares. The rating of the stock has changed to hold according to some ... Turning Spencer's outlook into concrete recommendations, Baird analyst Joel Beatty is pounding the table on two stocks that look especially compelling. According to the analyst, each name is ...BCEL forecast by analyst 3. Atreca stock fundamental checker 4. BCEL social sentiment 5. The Bright Future of Atreca Inc. Stock Forecast: Innovative Solutions and Strategic …ADMA Stock 12 Months Forecast. $6.00. (51.90% Upside) Based on 2 Wall Street analysts offering 12 month price targets for ADMA Biologics in the last 3 months. The average price target is $6.00 with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 51.90% change from the last price of $3.95.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Earnings announcement* for BCEL: Our vendor, Zacks Investment Research, hasn't provided us with the upcoming earnings report date. BCEL has a "high" Earnings Quality Ranking (EQR) for the 5th ...

FIXX Stock 12 Months Forecast. Based on 1 Wall Street analysts offering 12 month price targets for Homology Medicines in the last 3 months. The average price target is $1.50 with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 167.81% change from the last price of $0.56.

ALEC Stock 12 Months Forecast. $13.78. (169.14% Upside) Based on 9 Wall Street analysts offering 12 month price targets for Alector in the last 3 months. The average price target is $13.78 with a high forecast of $41.00 and a low forecast of $4.00. The average price target represents a 169.14% change from the last price of $5.12.The average Qifu Technology stock price prediction forecasts a potential upside of 57.86% from the current QFIN share price of $15.52. What is QFIN's forecast return on equity (ROE) for 2023-2025? (NASDAQ: QFIN) forecast ROE is N/A, which is considered weak.See Atreca, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ... The 4 analysts offering 1 year price forecasts for BCEL have a max estimate of — …The average Qifu Technology stock price prediction forecasts a potential upside of 57.86% from the current QFIN share price of $15.52. What is QFIN's forecast return on equity (ROE) for 2023-2025? (NASDAQ: QFIN) forecast ROE is N/A, which is considered weak.4/13 ratings generated profit. 31%. Average Return. -37.24%. reiterated a buy rating 10 months ago. Copying Do Kim 's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -37.24% per trade. 2 Years. dummy dummy.ATRECA, INC. stock price forecast for further price development down to -100.00% (time horizon: 1 day) and price target of 0.00 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) ATRECA, INC. share price prediction for 2024-01-12 with daily closed price projections$191.45 +1.76 +0.93% Find the latest analyst research for Atreca, Inc. Class A Common Stock (BCEL) at Nasdaq.com.See Atreca, Inc. (BCEL) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.4/13 ratings generated profit. 31%. Average Return. -37.24%. reiterated a buy rating 10 months ago. Copying Do Kim 's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -37.24% per trade. 2 Years. dummy dummy.Read Full Company Summary for BCEL here. View Atreca, Inc BCEL investment & stock information. Get the latest Atreca, Inc BCEL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Nov 29, 2023 · Based on short-term price targets offered by four analysts, the average price target for Atreca, Inc. comes to $5.25. The forecasts range from a low of $1.00 to a high of $10.00. The average price ... May 10, 2023 · On May 10, 2023, Atreca (NASDAQ:BCEL) announced its financial results for the first quarter of the year. The company reported Atreca Reports Q1 2023 Financial Results with Exceeding Analyst Estimates - Best Stocks Atreca, Inc. (BCEL.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Atreca, Inc. | Nasdaq: BCEL | NasdaqFind real-time NU - Nu Holdings Ltd stock quotes, company profile, news and forecasts from CNN Business.Stock Price Forecast. The 4 analysts offering 12-month price forecasts for SilverBow Resources Inc have a median target of 55.00, with a high estimate of 67.00 and a low estimate of 50.00. The ...Atreca, Inc. Class A Common Stock (BCEL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Atreca Inc (BCEL) Stock Price & News - Google Finance Home BCEL • NASDAQ Atreca Inc Follow Share $0.21 After Hours: $0.22 (2.90%) +0.0062 Closed: Nov 24, 3:00:17 PM GMT-5 · USD · NASDAQ ·... Apr 6, 2023 · Zacks Equity Research. April 6, 2023 at 9:55 AM · 3 min read. Shares of Atreca, Inc. (BCEL) have been struggling lately and have lost 20% over the past week. However, a hammer chart pattern was ... 2010. 90. John Orwin. https://www.atreca.com. Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified ...Based on analysts offering 12 month price targets for BCEL in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .BCEL Overview Stock Screener Earnings Calendar Sectors Nasdaq | BCEL U.S.: Nasdaq Atreca Inc. Cl A Watch Set a price target alert After Hours Last Updated: Nov 17, 2023 6:22 p.m. EST Delayed...

Nov 30, 2023 · The Atreca Inc. stock price gained 5.36% on the last trading day (Friday, 17th Nov 2023), rising from $0.209 to $0.220. During the last trading day the stock fluctuated 9.33% from a day low at $0.210 to a day high of $0.230. The price has been going up and down for this period, and there has been a -16.59% loss for the last 2 weeks. Earnings vs Market: BCEL is forecast to remain unprofitable over the next 3 years. High Growth Earnings : BCEL is forecast to remain unprofitable over the next 3 …Tecnoglass Inc. (NASDAQ:TGLS) released its earnings results on Monday, November, 6th. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.97 by $0.01. The company earned $210.30 million during the quarter, compared to analysts' expectations of $206.25 million.Instagram:https://instagram. best investment banking firmsnysearca splgbest platforms to trade forexnysearca pgx BCEL Stock 12 Months Forecast $2.00 (790.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Atreca in the last 3 months. The average price target … wells fargo mortgage cash out refinancebest options signals Cheniere Energy Inc. () Stock Market info Recommendations: Buy or sell Cheniere Energy stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Cheniere Energy share forecasts, stock quote and buy / sell signals below.According to present data Cheniere Energy's LNG shares and potentially its market environment have … futures brokers low margin Dec 1, 2023 · 12 analysts have issued twelve-month price objectives for CymaBay Therapeutics' stock. Their CBAY share price targets range from $12.00 to $34.00. On average, they anticipate the company's stock price to reach $22.27 in the next year. This suggests a possible upside of 24.4% from the stock's current price. View analysts price targets for CBAY ... Earnings vs Market: BCEL is forecast to remain unprofitable over the next 3 years. High Growth Earnings : BCEL is forecast to remain unprofitable over the next 3 …Find the latest Atreca, Inc. (BCEL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.